Erasca shares plunge 35% after Revolution Medicines accuses company of patent infringement
Updated
Updated · MarketWatch · Apr 27
Erasca shares plunge 35% after Revolution Medicines accuses company of patent infringement
4 articles · Updated · MarketWatch · Apr 27
Erasca's stock fell to $12.37 in after-hours trading following new accusations of patent infringement and trade secret theft by Revolution Medicines.
The allegations center on Erasca's ERAS-0015 cancer treatment, with Revolution demanding a halt to U.S. production and Erasca vowing to contest the claims.
This marks a deepening dispute after Revolution sent a legal letter on April 24, intensifying pressure on Erasca and raising uncertainty for investors.
Is Revolution's lawsuit timed to undermine Erasca's clinical success?
Can Erasca's own patent shield its promising drug from infringement claims?
How will this legal battle impact patient access to new cancer treatments?
Scientifically, which company's RAS-inhibitor shows more promise for patients?
Could a settlement be reached to avoid delaying these cancer therapies?
What does this dispute reveal about investment risks in the biotech sector?